Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Szarc Vel Szic, Katarzyna ^a   Op De Beeck, Ken ^a   Ratman, Dariusz ^b   Wouters, An ^a   Beck, Ilse M ^b   Declerck, Ken ^a   Heyninck, Karen ^b   Fransen, Erik ^a   Bracke, Marc ^b   De Bosscher, Karolien ^b   Lardon, Filip ^a   Van Camp, Guy ^a   Vanden Berghe, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; INTERLEUKIN 6; LAMININ; PROTEIN ADAM8; PROTEIN ANGPTL2; PROTEIN CSF1R; PROTEIN PLAT; PROTEIN TNFSF12; PROTEIN UPA; PROTEINASE; TRANSCRIPTOME; UNCLASSIFIED DRUG; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRMS1 GENE; CANCER CELL; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CHROMATIN; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYTOTHERAPY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; WITHANOLIDES;

EID: 84896882555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087850     Document Type: Article

References (65)

1. Website ACS (2013) What are the key statistics about breast cancer? pp. Available: http://www.cancer.org/cancer/breastcancer/detailedguide/breast- cancer-key-statistics.
2. Nanda R (2011) "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Semin Oncol 38: 254-262.
3. Santana-Davila R, Perez EA (2010) Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 3: 42.
4. Bhat WW, Lattoo SK, Razdan S, Dhar N, Rana S, et al. (2012) Molecular cloning, bacterial expression and promoter analysis of squalene synthase from Withania somnifera (L.) Dunal. Gene 499: 25-36.
5. Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5: 334-346. (Pubitemid 30660827)
6. Vanden Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K (2012) Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol 84: 1282-1291.
7. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG (2003) Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sciences 74: 125-132. (Pubitemid 37324225)
8. Stan SD, Hahm ER, Warin R, Singh SV (2008) Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68: 7661-7669.
9. Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, et al. (2013) Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model. J Natl Cancer Inst 105: 1111-1122.
10. Hahm ER, Singh SV (2012) Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. Cancer Lett.
11. Stan SD, Zeng Y, Singh SV (2008) Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60 Suppl 1: 51-60.
12. Widodo N, Priyandoko D, Shah N, Wadhwa R, Kaul SC (2010) Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling. PLoS One 5: e13536.
13. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, et al. (2011) Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 129: 2744-2755.
14. Grin B, Mahammad S, Wedig T, Cleland MM, Tsai L, et al. (2012) Withaferin a alters intermediate filament organization, cell shape and behavior. PLoS One 7: e39065.
15. Lee J, Sehrawat A, Singh SV (2012) Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat 136: 45-56.
16. Ndlovu MN, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, et al. (2009) Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol 29: 5488-5504.
17. Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J, et al. (2007) Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 282: 4253-4264. (Pubitemid 47100978)
18. Lee J, Hahm ER, Singh SV (2010) Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 31: 1991-1998.
19. Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, et al. (2013) Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer 16: 23-31.
20. Gentleman R (2005) Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer Science+Business Media. xix, 473 p. p.
21. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
22. Steffan JJ, Koul HK (2011) Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor. Cancer Lett 310: 109-117.
23. Belguise K, Kersual N, Galtier F, Chalbos D (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24: 1434-1444. (Pubitemid 40343123)
24. Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, et al. (2007) FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 7: 17.
25. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
26. Zambelli F, Prazzoli GM, Pesole G, Pavesi G (2012) Cscan: finding common regulators of a set of genes by using a collection of genome-wide ChIP-seq datasets. Nucleic Acids Res 40: W510-515.
27. Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, et al. (2012) Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics 13: 619.
28. Brown KD (2013) Transglutaminase 2 and NF-kappaB: an odd couple that shapes breast cancer phenotype. Breast Cancer Res Treat 137: 329-336.
29. Endo M, Nakano M, Kadomatsu T, Fukuhara S, Kuroda H, et al. (2012) Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res 72: 1784-1794.
30. Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, et al. (2012) Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res 14: R23.
31. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, et al. (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73: 1128-1141.
32. Ma L, Lan F, Zheng Z, Xie F, Wang L, et al. (2012) Epidermal growth factor (EGF) and interleukin (IL)-1beta synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer 11: 79.
33. Hurst DR, Welch DR (2011) Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 286: 107-180.
34. De Wever O, Hendrix A, De Boeck A, Westbroek W, Braems G, et al. (2010) Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol 54: 887-896.
35. Chi P, Allis CD, Wang GG (2010) Covalent histone modifications- miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469.
36. Vyas AR, Singh SV (2013) Molecular Targets and Mechanisms of Cancer Prevention and Treatment by Withaferin A, A Naturally Occurring Steroidal Lactone. AAPS J.
37. Chia J, Kusuma N, Anderson R, Parker B, Bidwell B, et al. (2007) Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol 170: 2135-2148. (Pubitemid 47339285)
38. Pouliot N, Kusuma N (2013) Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adh Migr 7: 142-149.
39. Miyazaki K (2006) Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 97: 91-98.
40. Subbaram S, Dipersio CM (2011) Integrin alpha3beta1 as a breast cancer target. Expert Opin Ther Targets 15: 1197-1210.
41. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, et al. (2012) A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs 30: 604-610.
42. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, et al. (2011) The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 8: 9.
43. Castellana B, Escuin D, Peiro G, Garcia-Valdecasas B, Vazquez T, et al. (2012) ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas. J Cancer 3: 175-183.
44. Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, et al. (2011) AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 71: 7091-7102.
45. Mazar AP, Ahn RW, O'Halloran TV (2011) Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des 17: 1970-1978.
46. Rockway TW, Giranda VL (2003) Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 9: 1483-1498. (Pubitemid 36758312)
47. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, et al. (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997. (Pubitemid 351272216)
48. Tian M, Neil JR, Schiemann WP (2011) Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 23: 951-962.
49. Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, et al. (2009) Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 125: 1778-1785.
50. Yu H, Simons DL, Segall I, Carcamo-Cavazos V, Schwartz EJ, et al. (2012) PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS One 7: e51239.
51. Cock-Rada A, Weitzman JB (2013) The methylation landscape of tumour metastasis. Biol Cell 105: 73-90.
52. Nijwening JH, Geutjes EJ, Bernards R, Beijersbergen RL (2011) The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence. PLoS One 6: e25235.
53. He Y, Korboukh I, Jin J, Huang J (2012) Targeting protein lysine methylation and demethylation in cancers. Acta Biochim Biophys Sin (Shanghai) 44: 70-79.
54. Johnson DG, Dent SY (2013) Chromatin: receiver and quarterback for cellular signals. Cell 152: 685-689.
55. Pereira F, Barbachano A, Silva J, Bonilla F, Campbell MJ, et al. (2011) KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet 20: 4655-4665.
56. Ramadoss S, Chen X, Wang CY (2012) Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J Biol Chem 287: 44508-44517.
57. Berry WL, Janknecht R (2013) KDM4/JMJD2 Histone Demethylases: Epigenetic Regulators in Cancer Cells. Cancer Res 73: 2936-2942.
58. Blair LP, Cao J, Zou MR, Sayegh J, Yan Q (2011) Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) 3: 1383-1404.
59. Natoli G, Testa G, De Santa F (2009) The future therapeutic potential of histone demethylases: A critical analysis. Curr Opin Drug Discov Devel 12: 607-615.
60. Floor SL, Dumont JE, Maenhaut C, Raspe E (2012) Hallmarks of cancer: of all cancer cells, all the time? Trends Mol Med 18: 509-515.
61. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780.
62. Albini A, Tosetti F, Li VW, Noonan DM, Li WW (2012) Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9: 498-509.
63. Brunner N, Spang-Thomsen M, Vindelov L, Nielsen A (1983) Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br J Cancer 47: 641-647. (Pubitemid 13094901)
64. Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23: 2183-2184. (Pubitemid 47394121)
65. Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9: 253-264.